Imagine diagnosing melanoma not with a scalpel, but with a sticker. DermTech is betting $260M that their Smart Sticker technology can detect skin cancer genomic markers non-invasively, disrupting a $10B+ dermatology market by replacing painful biopsies with adhesive genomics.

"The real moat isn't the sticker—it's the genomic data layer that turns equivocal lesions into definitive diagnoses, creating a high-margin SaaS-like recurring revenue stream from dermatologists."

The tech stack—jQuery, Tailwind, Bootstrap—feels deliberately utilitarian. This isn't a consumer-facing app chasing viral UX; it's a clinical portal designed for speed and reliability in high-stakes environments. The absence of Trustpilot reviews isn't a red flag—it's expected. Medical device companies don't solicit public reviews; they build evidence through peer-reviewed studies and payer contracts. Their top keywords reveal the strategy: 'pla cancer' (260 monthly volume) targets the precise diagnostic ambiguity they solve, while branded terms capture their niche audience.

• Non-invasive genomics replaces surgical biopsies for equivocal lesions
• Smart Sticker™ captures mRNA for 23 melanoma-associated markers
• Revenue model: high-margin recurring test fees ($200-$400 per test)
• B2B2C strategy: dermatologists as gatekeepers, not consumers
• Clinical evidence drives payer reimbursement, not SEO